Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology Summer Symposium
OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Slightly above 62% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Ocuphire |
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinctionFARMINGTON HILLS, Mich., Aug. 28, 2023 Ocuphire Pharma, Inc. , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that data from its Phase 2 clinical trial of APX3330 in Diabetic Retinopathy
Read at finance.yahoo.com
Ocuphire Pharma Fundamental Analysis
We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Ocuphire Pharma is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Ocuphire Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.
Peers
Ocuphire Pharma Related Equities
RVPHW | Reviva Pharmaceuticals | 23.53 | ||||
EYEN | Eyenovia | 19.05 | ||||
RNAZ | Transcode Therapeutics | 11.76 | ||||
CKPT | Checkpoint Therapeutics | 8.07 | ||||
EYPT | Eyepoint Pharmaceuticals | 7.19 | ||||
KOD | Kodiak Sciences | 4.92 | ||||
SLS | Sellas Life | 4.27 | ||||
RIGL | Rigel Pharmaceuticals | 3.99 | ||||
FBIO | Fortress Biotech | 2.55 | ||||
PLX | Protalix Biotherapeutics | 1.81 | ||||
CGTX | Cognition Therapeutics | 2.27 | ||||
FBIOP | Fortress Biotech | 2.85 | ||||
MBIO | Mustang Bio | 4.55 | ||||
RVPH | Reviva Pharmaceuticals | 8.06 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |